Media about us

13 June 2017

Pfizer eyes building another plant in Russia

ThePharmaLetter

US pharma giant Pfizer (NYSE: PFE) is considering building another manufacturing plant in Russia during the next several years, which is expected to be located in the Tatarstan Republic, one of Russia’s richest and economically developed regions. In addition on May 30, Pfizer officially started building its first Russian plant in the Kaluga Vorsino technopark, which takes place in cooperation with its local partner NovaMedica.

05 June 2017

Russian partnerships: Pfizer and NovaMedica break ground on aseptic plant

Dan Stanton / InPharma Technologist

05 June 2017

The three factors crucial to effectiveness in healthcare

SPIEF-2017. Panel discussion "The three factors crucial to effectiveness in healthcare". “The problem and task is to boost the system’s performance within the budget available for now. That does not mean the system needs no more money, that means spending must be efficient,” said Leonid Melamed, Chairman of the Board of Directors, Team Drive.

01 June 2017

Plant to produce Pfizer sterile injectables for Russia gets under way

Eric Palmer / Fierce Pharma

Russia's NovaMedica is building a new sterile injectables plant in the Kaluga region where it will produce 30 of Pfizer’s sterile injected generic meds for the local market.

01 June 2017

Construction of a new pharmaceutical plant started in Vorsino Industrial Park

GMP News

On May 30, Vorsino Industrial Park in the Kaluga region hosted an official ceremony to mark the start of construction of an advanced biopharmaceutical production facility owned by NovaMedica LLC (a RUSNANO investment project).

31 May 2017

Construction of Pfizer-sponsored pharmaceutical factory starts in Russia

Construction.ru

A ground-breaking ceremony of a pharmaceutical factory was held on Tuesday in Vorsino technology park located near the Russian city of Kaluga. American company Pfizer is an investor of the enterprise's building project. The main partner of the project is NovaMedica, a portfolio company of the Russian government-owned company Rusnano engaged in the development of nanotechnology.

29 May 2017

Russia – USA. The bilateral business interest in investment remains high.

TASS

In their first talks, Russia’s President Vladimir Putin and the US President Donald Trump noted the importance of restoring full-scale economic partnership, with due account of the fact that in 2016 Russian-American projects started and continued virtually across the entire economy. The numbers include the US investments in Russian export-oriented and import-substituting industries. A number of such projects began in 2016 alone, with Pfizer’s pharmaceutical factory and Novamedica Company in the Kaluga Region among them.

29 May 2017

US Companies in Russia Regularly Confirm Determination to Stay - Embassy

Sputnik

Minister-Counselor of the Russian Embassy in the United States Denis Gonchar said in anterview with Sputnik on Monday that American companies working in Russia regularly confirm that they are not going to leave the country. One of his examples that US global pharmaceutical corporation Pfizer and Russian pharmaceutical company NovaMedica signed a strategic partnership agreement, including the construction of a manufacturing plant in the Vorsino industrial park for production of more than 30 vital medicinal products and the work of joint technical laboratories in Moscow.

Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

John Carroll / Endpoints News

Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.

02 May 2017

Epic Sciences nets $40M for cancer liquid biopsy

Amirah Al Idrus / FierceBiotech

Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.